Payment overview · 2025
General Payments
$1,015.00
29 reported records · 18 companies
Healthcare provider profile · identity verified
Inoel Rivera Ramirez, M.D.
Allopathic & Osteopathic Physicians|Urology · ORLANDO, FL · NPI 1811984131
Verified facts
What the public records show
CMS Open Payments records show Inoel Rivera Ramirez, M.D. received $1,015.00 in general payments during 2025 across 29 reported records.
Ferring Pharmaceuticals Inc. accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Nubeqa.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Nubeqa as an associated drug or biological on 24369 records involving 9557 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Nubeqa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ferring Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $229.44 | 22.6% | 8 | 2025 |
| UROGEN PHARMA, INC. | Unresolved — no canonical attribution shown | $194.35 | 19.1% | 4 | 2025 |
| Myriad Genetic Laboratories, Inc. | Unresolved — no canonical attribution shown | $130.09 | 12.8% | 1 | 2025 |
| Profound Medical Corp. | Unresolved — no canonical attribution shown | $119.60 | 11.8% | 1 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $41.91 | 4.1% | 2 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $30.04 | 3.0% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $28.58 | 2.8% | 1 | 2025 |
| IMMUNITYBIO, INC. | Unresolved — no canonical attribution shown | $28.35 | 2.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $28.05 | 2.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.82 | 2.7% | 1 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $27.64 | 2.7% | 1 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $26.63 | 2.6% | 1 | 2025 |
| Guard Medical Inc. | Unresolved — no canonical attribution shown | $21.37 | 2.1% | 1 | 2025 |
| CIVCO Medical Instruments | Unresolved — no canonical attribution shown | $20.46 | 2.0% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$17.61 | 1.7% | 1 | 2025 |
| CONMED Corporation | Unresolved — no canonical attribution shown | $15.68 | 1.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $13.88 | 1.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.50 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,015.00 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ADSTILADRIN Normalized: adstiladrin |
Biological | Ferring Pharmaceuticals Inc. | $229.44 | 8 | 2025 |
Source payment records
|
|||||
| JELMYTO Normalized: jelmyto |
Drug | UROGEN PHARMA, INC. | $143.60 | 1 | 2025 |
Source payment records
|
|||||
| PROLARIS Normalized: prolaris |
Device | Myriad Genetic Laboratories, Inc. | $130.09 | 1 | 2025 |
Source payment records
|
|||||
| Tulsa-Pro Normalized: tulsa pro |
Device | Profound Medical Corp. | $119.60 | 1 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Biotech, Inc., Janssen Scientific Affairs, LLC | $69.55 | 3 | 2025 |
Source payment records
|
|||||
| ZUSDURI Normalized: zusduri |
Drug | UROGEN PHARMA, INC. | $43.66 | 2 | 2025 |
Source payment records
|
|||||
| Bard Urinary Drainage Bag Normalized: bard urinary drainage bag |
Device | Becton, Dickinson and Company | $30.04 | 1 | 2025 |
Source payment records
|
|||||
| ELIGARD Normalized: eligard |
Drug | TOLMAR, INC. | $28.58 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $28.58 | 1 | 2025 |
Source payment records
|
|||||
| ANKTIVA Normalized: anktiva |
Drug | IMMUNITYBIO, INC. | $28.35 | 1 | 2025 |
Source payment records
|
|||||
| LithoVue Normalized: lithovue |
Device | Boston Scientific Corporation | $28.05 | 1 | 2025 |
Source payment records
|
|||||
| Nubeqa Normalized: nubeqa |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $27.82 | 1 | 2025 |
Source payment records
|
|||||
| Xofigo Normalized: xofigo |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $27.82 | 1 | 2025 |
Source payment records
|
|||||
| PIPELINE Normalized: pipeline |
Device | Janssen Scientific Affairs, LLC | $27.64 | 1 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $26.63 | 1 | 2025 |
Source payment records
|
|||||
| NPSEAL Normalized: npseal |
Device | Guard Medical Inc. | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| AIRSEAL Normalized: airseal |
Device | CONMED Corporation | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| LUPRON DEPOT Normalized: lupron depot |
Drug | ABBVIE INC. | $13.88 | 1 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | PFIZER INC. | $13.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Nubeqa nubeqa |
2025 | Nubeqa | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Nubeqa open payments reported associated product |
CMS Open Payments — General Payments 24369 supporting records · 9557 recipient NPIs · example record 1225434669 |
Nubeqa · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Tamsulosin Hcl | Tamsulosin Hcl | 248 | 103 |
| Finasteride | Finasteride | 137 | 55 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 52 | 22 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 27 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 25 |
| Diazepam | Diazepam | 25 | 24 |
| Myrbetriq | Mirabegron | 23 | 11 |
| Nubeqa | Darolutamide | 19 | suppressed |
| Gemcitabine Hcl | Gemcitabine Hcl | 16 | 12 |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Bicalutamide | Bicalutamide | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | 12 |
| Silodosin | Silodosin | 13 | suppressed |
| Docetaxel | Docetaxel | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,015.00 · 29 records | Ferring Pharmaceuticals Inc. | ADSTILADRIN, AIRSEAL, ANKTIVA, Bard Urinary Drainage Bag, ELIGARD, ERLEADA, JATENZO, JELMYTO, LUPRON DEPOT, LithoVue, MI CANCER SEEK, NPSEAL, Nubeqa, ORGOVYX, PIPELINE, PROLARIS, TALZENNA, Tulsa-Pro, XTANDI, Xofigo, ZUSDURI | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Nubeqa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error